NF1 and glioblastoma: To test the predictions of our in vitro mathematical models, we treated murine (Nf1-/-DNp53), human (LN229), and primary (B165) GBM cell lines with three different doses of TMZ, previously tested for circadian effects [11], at either a model-predicted optimal (CT4) or suboptimal (CT16) circadian time.